초록 ▼

A kit is described including at least one container including a predetermined quantity of sterilized biodegradable carriers in a powder form having a treatment agent disposed therein. The kit further includes a delivery device for delivering the predetermined quantity of sterilized biodegradable car

A kit is described including at least one container including a predetermined quantity of sterilized biodegradable carriers in a powder form having a treatment agent disposed therein. The kit further includes a delivery device for delivering the predetermined quantity of sterilized biodegradable carriers with the treatment agent disposed therein to a treatment site. In other embodiments, methods are described for producing the sterilized treatment agent loaded biodegradable carriers and delivering the sterilized carriers to a treatment site.

대표청구항 ▼

1. A method comprising: introducing a predetermined quantity of biodegradable carriers having a treatment agent disposed therein into a container, wherein the biodegradable carriers comprise nanoparticles or microparticles and are introduced into the container in the form of a solution;lyophilizing

1. A method comprising: introducing a predetermined quantity of biodegradable carriers having a treatment agent disposed therein into a container, wherein the biodegradable carriers comprise nanoparticles or microparticles and are introduced into the container in the form of a solution;lyophilizing the predetermined quantity of biodegradable carriers to form a powder within the container, wherein lyophilizing comprises exposing the biodegradable carriers to a reduced pressure of less than 10−5 Mpa;after lyophilizing, conditioning the powder of biodegradable carriers to remove moisture, wherein conditioning comprises applying a vacuum to the container followed by introducing an inert gas into the container, wherein the inert gas is one of a nitrogen gas and an argon gas;after conditioning, cooling the powder of biodegradable carriers; andafter cooling, sterilizing the container and the conditioned powder of biodegradable carriers, wherein sterilizing comprises exposing the container and the biodegradable carriers to one of a gamma ray or an electron beam. 2. The method of claim 1 further comprising: placing the lyophilized biodegradable carriers and container in a porous pouch prior to sterilizing. 3. The method of claim 1 wherein the treatment agent is capable of inhibiting a biological process contributing to nephropathy. 4. The method of claim 1 wherein the container is a syringe. 5. The method of claim 4 further comprising: placing a filter over a tip of the syringe prior to sterilizing. 6. The method of claim 1 wherein the container with the biodegradable carriers are exposed to one of the gamma ray or the electron beam at a dose of from 10 kGy to 30 kGy. 7. The method of claim 1 further comprising: sealing the sterilized container with the sterilized biodegradable carriers therein within a pouch impermeable to humidity and air. 8. The method of claim 1 further comprising: introducing an antioxidant into the container to protect the biodegradable carriers from moisture and oxidative agents. 9. The method of claim 1 wherein conditioning is performed while the powder of biodegradable carriers is within the container. 10. The method of claim 1 wherein the treatment agent is an mTOR inhibitor selected from one of everolimus or zotarolimus. 11. The method of claim 1 wherein the biodegradable carriers are made of a polymer selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), poly (L-lactide), poly (D,L-lactide), poly (glycolide), poly (lactide-co-glycolide), polycaprolactone, polyanhydride, polydiaxanone, polyorthoester, polyamino acids, and poly (trimethylene carbonate). 12. The method of claim 1 wherein the nanoparticles or microparticles have a size of from 1 micron to 100 microns. 13. The method of claim 1 wherein cooling comprises cooling the powder of biodegradable carriers to a temperature of between −4 degrees Celsius and 10 degrees Celsius.